ASH 2023 | OxCOM: monitoring monoclonal gammopathies for progression to active myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, introduces the OxCOM program for monitoring patients with monoclonal gammopathies (MG). Inspired by the iStopMM trial (NCT03327597), this program has successfully monitored low- to high-risk MG patients to identify progression to active myeloma. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Adaptive Biotech: Honoraria, Membership on an entity’s Board of Directors or advisory committees; GSK: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Menarini Stemline: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Recordati: Honoraria; BMS ( Celgene): Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding.
